Evercore ISI Group Reinstates Outperform on Mirum Pharmaceuticals, Announces $62 Price Target
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group analyst Gavin Clark-Gartner has reinstated Mirum Pharmaceuticals (NASDAQ:MIRM) with an Outperform rating and announced a $62 price target.
October 17, 2023 | 3:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mirum Pharmaceuticals has been reinstated with an Outperform rating by Evercore ISI Group, with a price target of $62.
The reinstatement of the Outperform rating and the setting of a $62 price target by Evercore ISI Group indicates a positive outlook for Mirum Pharmaceuticals. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100